Athersys Inc (ATHXQ)
Athersys, Inc. is an OTC Markets-listed common stock of a clinical-stage biotechnology company focused on regenerative medicine. The company’s principal product candidate is MultiStem, an allogeneic stem cell therapy being studied for potential use across neurological, inflammatory and immune, cardiovascular, and other critical care indications. Founded in 1995 and based in Cleveland, Ohio, Athersys operated as a development-stage biotech issuer rather than a commercial drug company. On January 5, 2024, the company and its affiliates filed for Chapter 11 bankruptcy, and that case was later converted to Chapter 7 on September 24, 2024.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ATHX.Q
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 20, 2026
|
—
|
—
|
—
|
0.061 K
|
—
|
—
|
—
|
—
|
—
|
—
|